Lumis Global Pharmaceuticals

Lumis Global Pharmaceuticals is a China-based pharmaceutical company focused on the research, export, and supply of pharmaceutical raw materials and active pharmaceutical ingredients. Publicly available evidence indicates the company operated an API-related manufacturing, repackaging, relabeling, and holding facility in Wuhan, Hubei, and exported products to overseas customers. The business appears to be oriented toward commercial supply rather than novel drug discovery, with available records emphasizing API sourcing and regulatory compliance rather than a therapeutic development pipeline. FDA records show the company received a warning letter in March 2017 related to CGMP and labeling deficiencies at its Wuhan facility. Available data also suggest the underlying Wuhan operating entity remained listed as active in Chinese business databases, although independent confirmation from an official corporate website is limited.